Target intelligence / Profile preview

Immunoglobulin heavy constant gamma 1 (IGHG1)

Target
IGHG1
Molecular classification
Other (Immunoglobulin constant region component)
01

Overview

Immunoglobulin heavy constant gamma 1 (IGHG1) encodes the constant region of the heavy chain of IgG1, the most prevalent subclass of IgG antibodies in human serum[1][4][7]. The IgG1 molecule is comprised of two heavy chains (with IGHG1 as their constant region component) and two light chains, forming a basic Y-shaped configuration critical for specific antigen recognition (via variable domains) and immune effector functions (via the Fc domain)[5][8][9]. IGHG1 enables the antibody's interaction with Fc gamma receptors (FcγR) and complement proteins, mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity[1][2][4]. IgG1-based therapeutic monoclonal antibodies use this domain as the protein scaffold due to its potent effector functions; however, IGHG1 is not a direct drug target itself, but an essential building block for antibody-based drugs[8]. Altered expression or structure of IGHG1 can be associated with autoimmune disease, infection susceptibility, and various immune pathologies[1][4][8].

Other names
Ig gamma-1 chain C regionIg gamma-1 chain C region EUIg gamma-1 chain C region KOLIg gamma-1 chain C region NIEImmunoglobulin gamma 1 (Gm marker)Constant region of heavy chain of IgG1G1m markerIGHG1
02

Mechanism of action

Antigen recognition (via antibody variable region); Effector function via Fc domain (complement activation, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity)

03

Biological functions

Immune responseAntigen bindingAntibody-dependent cellular cytotoxicityComplement-dependent cytotoxicity
04

Disease associations

InfectionCancerInflammationOther (Autoimmune disease, Immunodeficiency)
05

Safety considerations

Risk of immunogenicity and infusion reactions with therapeutic monoclonal antibodies based on IgG1Possible hypersensitivity or allergy in rare contexts
06

Biomarkers

IgG1 serum levels (biomarker for some immune disorders, infection, and response to monoclonal antibody therapeutics)

Beyond the preview

Go deeper on Immunoglobulin heavy constant gamma 1 (IGHG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy constant gamma 1 (IGHG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call